Cerebrospinal fluid plasminogen activator inhibitor-1: A prognostic factor in posthaemorrhagic hydrocephalus

Acta Paediatrica, International Journal of Paediatrics

Volumn 86, Issue 9, 1997, Pages 995-998

  Hansen, A ^a   Whitelaw, A ^b   Lapp, C ^a   Brugnara, C ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Intraventricular haemorrhage; Newborn infant; Plasminogen activator inhibitor

Indexed keywords

FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BRAIN VENTRICLE HEMORRHAGE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRINOLYTIC THERAPY; HUMAN; HYDROCEPHALUS; NEWBORN; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030868202     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.1997.tb15186.x     Document Type: Article

References (26)

1. Volpe JJ. Neurology of the newborn. Philadelphia: Saunders, 1995: 403-63
2. Hill A, Shackelford GD, Volpe JJ. A potential mechanism of pathogenesis for early posthemorrhagic hydrocephalus in the premature newborn. Pediatrics 1984; 73: 19-21
3. Whitelaw A. Endogenous fibrinolytic activity in neonatal cerebrospinal fluid. Eur J Pediatr 1993; 152: 928-30
4. Whitelaw A, Creighton L, Gaffney P. Fibrinolytic activity in cerebrospinal fluid after intraventricular haemorrhage. Arch Dis Child 1991; 66: 808-9
5. Whitelaw A, Mowinckel M-C, Fellman V, Abildgaard U. Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Eur J Pediatr 1996; 155: 117-9
6. Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular clot with urokinase in a canine model. 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus. Neurosurgery 1986; 19: 553-72
7. Brinker T, Seifert V, Dietz H. Subacute hydrocephalus after experimental subarachnoid haemorrhage: its prevention by intrathecal fibrinolysis with recombinant tissue plasminogen activator. Neurosurgery 1992; 31: 306-12
8. Findlay JM, Weir BKA, Stolley DE. Lysis of intraventricular hematoma with tissue plasminogen activator. Neurosurgery 1991; 74: 803-7
9. Mayfrank L, Lippitz B, Groth M, Bertalanffy H, Gilsbach JM. Effect of recombinant tissue plasminogen activator on clot lysis and ventricular dilatation in the treatment of severe intraventricular haemorrhage. Acta Neurochir 1993; 122: 32-8
10. Rohde V, Schaller C, Hassler WE. Intraventricular recombinant tissue plasminogen activator for lysis of intraventricular haemorrhage. J Neurol Neurosurg Psychiatry 1995; 58: 447-51
11. Whitelaw A, Rivers R, Creighton L, Gaffney P. Low dose intraventricular fibrinolytic therapy to prevent posthaemorrhagic hydrocephalus. Arch Dis Child 1992; 67: 12-4
12. Hudgins RJ, Boydston WR, Hudgins PA, Adler SR. Treatment of intraventricular hemorrhage in the premature infant with urokinase. Pediatr Neurosurg 1994; 20: 190-7
13. Whitelaw A, Saliba E, Fellman V, Mowinckel M-C, Acolet D, Marlow N. Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. Arch Dis Child 1996; 75: F20-6
14. Kruithof EKO. Plasminogen activator inhibtors - a review. Enzyme 1988; 40: 113-21
15. Loskutoff DJ. Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Semin Thromb Hemost 1988; 14: 100-9
16. Robbins KC, Barlow GH, Nguyen G, Samama MM. Comparison of plasminogen acivators. Semin Thromb Hemost 1987; 13(2): 131-8
17. Luskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115
18. Corrigan JJ, Jeter MA. Tissue-type plasminogen activator, plasminogen activator inhibitor and histidine rich glycoproteins in stressed human newborns. Pediatrics 1992; 89: 43-6
19. Krishnamurti C, Alving BM. Plasminogen activator inhibtor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost 1992; 18: 67-79
20. Rao JS, Chen M, Festoff BW. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in normal human cerebrospinal fluid. J Neurosci Res 1993; 34: 340-5
21. Sutton R, Keohane ME, Van den Berg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994; 5: 167-71
22. Levene MI. Measurement of the growth of the lateral ventricles in preterm infants with real time ultrasound. Arch Dis Child 1981; 56: 900-4
23. Whitelaw A. Neonatal hydrocephalus: aetiology, clinical assessment, prognosis and non-surgical treatment. In: Levene MI, Lilford RJ, editors. Fetal and neonatal neurology and neurosurgery, 2nd ed. Edinburgh: Churchill Livingstone, 1995: 645-59
24. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529-34
25. Larroche JC. Post-hemorrhagic hydocephalus in infancy: anatomical study. Biol Neonate 1972; 20: 287-99
26. Whitelaw A, Mowinckel M-C, Abildgaard U. Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? Acta Paediatr 1995; 84: 933-6